Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 238.9% in November

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 105,400 shares, an increase of 238.9% from the October 31st total of 31,100 shares. Based on an average daily trading volume, of 74,600 shares, the days-to-cover ratio is currently 1.4 days. Currently, 2.8% of the company’s shares are short sold.

Altamira Therapeutics Price Performance

Shares of Altamira Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $0.42. 81,348 shares of the company’s stock traded hands, compared to its average volume of 721,908. The stock has a 50 day moving average of $0.54 and a 200-day moving average of $0.95. Altamira Therapeutics has a 12 month low of $0.40 and a 12 month high of $17.20.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.